MX2023009630A - Composiciones en disolución acuosa para aumentar la estabilidad de las proteínas diméricas manipuladas genéticamente. - Google Patents
Composiciones en disolución acuosa para aumentar la estabilidad de las proteínas diméricas manipuladas genéticamente.Info
- Publication number
- MX2023009630A MX2023009630A MX2023009630A MX2023009630A MX2023009630A MX 2023009630 A MX2023009630 A MX 2023009630A MX 2023009630 A MX2023009630 A MX 2023009630A MX 2023009630 A MX2023009630 A MX 2023009630A MX 2023009630 A MX2023009630 A MX 2023009630A
- Authority
- MX
- Mexico
- Prior art keywords
- aqueous solution
- stability
- increase
- compositions
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2102258.7A GB202102258D0 (en) | 2021-02-17 | 2021-02-17 | Novel composition |
| PCT/US2022/016864 WO2022178175A1 (en) | 2021-02-17 | 2022-02-17 | Aqueous solution compositions for increasing stability of engineered dimeric proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009630A true MX2023009630A (es) | 2023-11-06 |
Family
ID=75338972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009630A MX2023009630A (es) | 2021-02-17 | 2022-02-17 | Composiciones en disolución acuosa para aumentar la estabilidad de las proteínas diméricas manipuladas genéticamente. |
Country Status (12)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023225513A1 (en) * | 2022-05-16 | 2023-11-23 | Inhibrx, Inc. | Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2476934C (en) * | 2002-02-27 | 2009-06-16 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
| AU2004216298B2 (en) * | 2003-02-28 | 2009-04-23 | Chugai Seiyaku Kabushiki Kaisha | Stabilized protein-containing formulations |
| PT1684719E (pt) * | 2003-11-14 | 2012-02-03 | Baxter Int | Composições de alfa-1-antitripsina e métodos de tratamento utilizando estas composições |
| JP4965446B2 (ja) * | 2004-08-31 | 2012-07-04 | ノヴォ ノルディスク アー／エス | ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス（ヒドロキシメチル）アミノメタンの使用 |
| JP2008543839A (ja) * | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| KR20080071192A (ko) * | 2005-11-22 | 2008-08-01 | 와이어쓰 | 면역글로불린 융합 단백질 제형 |
| GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| EP2598167B1 (en) * | 2010-07-30 | 2015-04-01 | Arecor Limited | Stabilized aqueous antibody compositions |
| BR112013025845A2 (pt) * | 2011-04-07 | 2018-09-04 | Glaxosmithkline Llc | formulações com viscosidade reduzida |
| SMT201900520T1 (it) | 2011-06-28 | 2019-11-13 | Inhibrx Lp | Polipeptidi di fusione serpinici e relativi metodi d'uso |
| KR20140137347A (ko) * | 2012-01-10 | 2014-12-02 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도 |
| US9527890B2 (en) * | 2013-06-18 | 2016-12-27 | The Brigham And Womens's Hospital, Inc. | FC receptor (FcRn) binding peptides and uses thereof |
| CN110903398B (zh) * | 2014-01-15 | 2023-08-15 | 豪夫迈·罗氏有限公司 | 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体 |
| US20170190762A1 (en) * | 2014-06-11 | 2017-07-06 | Beth Israel Deaconess Medical Center, Inc. | Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases |
| MX2017005467A (es) * | 2014-10-27 | 2017-11-30 | Inhibrx Lp | Polipéptidos de fusión de serpina y métodos para utilizar los mismos. |
| GB201703063D0 (en) * | 2017-02-24 | 2017-04-12 | Arecor Ltd | Stabilized antibody protein solutions |
| GB201721846D0 (en) * | 2017-12-22 | 2018-02-07 | Arecor Ltd | Novel composition |
-
2021
- 2021-02-17 GB GBGB2102258.7A patent/GB202102258D0/en not_active Ceased
-
2022
- 2022-02-17 AU AU2022224607A patent/AU2022224607A1/en active Pending
- 2022-02-17 EP EP22709101.4A patent/EP4294372A1/en active Pending
- 2022-02-17 CN CN202280028860.9A patent/CN117279624A/zh active Pending
- 2022-02-17 JP JP2023549616A patent/JP2024506718A/ja active Pending
- 2022-02-17 IL IL305142A patent/IL305142A/en unknown
- 2022-02-17 BR BR112023016442A patent/BR112023016442A2/pt unknown
- 2022-02-17 KR KR1020237031527A patent/KR20230147140A/ko active Pending
- 2022-02-17 MX MX2023009630A patent/MX2023009630A/es unknown
- 2022-02-17 WO PCT/US2022/016864 patent/WO2022178175A1/en not_active Ceased
- 2022-02-17 US US17/674,713 patent/US20220265788A1/en not_active Abandoned
- 2022-02-17 CA CA3208704A patent/CA3208704A1/en active Pending
-
2024
- 2024-09-30 US US18/902,711 patent/US20250177501A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023016442A2 (pt) | 2023-10-10 |
| US20220265788A1 (en) | 2022-08-25 |
| AU2022224607A1 (en) | 2023-08-31 |
| WO2022178175A1 (en) | 2022-08-25 |
| US20250177501A1 (en) | 2025-06-05 |
| CN117279624A (zh) | 2023-12-22 |
| KR20230147140A (ko) | 2023-10-20 |
| CA3208704A1 (en) | 2022-08-25 |
| GB202102258D0 (en) | 2021-03-31 |
| EP4294372A1 (en) | 2023-12-27 |
| IL305142A (en) | 2023-10-01 |
| JP2024506718A (ja) | 2024-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Söderhäll et al. | The properties and purification of a Blaberus craniifer plasma protein which enhances the activation of haemocyte prophenoloxidase by a β 1, 3-glucan | |
| EA201590611A1 (ru) | Новые молекулы, связывающие il-17a, и их медицинское применение | |
| BR112021018776A2 (pt) | Vetores de vírus adenoassociado recombinante | |
| PE20191033A1 (es) | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| JOP20240283A1 (ar) | تركيبة منظف الشعر وفروة الرأس لإزالة السموم، طرق استخدامها واستخداماتها | |
| DOP2014000029A (es) | Proteínas y péptidos modificados. | |
| MX381183B (es) | Proteínas de fusión de serpina-fc de inmunoglobulina de humano y método de purificación de las mismas. | |
| MX2019000898A (es) | Amortiguador de lavado de cromatografia de afinidad. | |
| Barrett | Human cathepsin D | |
| MX2022011071A (es) | Composiciones que mejoran la estabilidad del poxvirus. | |
| WO2022207839A3 (en) | Stabilized pre-fusion piv3 f proteins | |
| GEAP202516650A (en) | Stabilized pre-fusion hmpv fusion proteins | |
| CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
| BR112023016442A2 (pt) | Composições de soluções aquosas para aumentar a estabilidade de proteínas diméricas modificadas | |
| US12331230B2 (en) | Protein-based adhesive and its modification | |
| BR112024001179A2 (pt) | Aminoácido supramolecular ou sal do mesmo, e método de preparação do mesmo e aplicação do mesmo | |
| DE60227670D1 (de) | Aminosäuren-enthaltende zusammensetzungen, geeignet zur wundheilung, insbesondere zur behandlung des auges | |
| Engle et al. | Characterization of two myotoxic proteins from venom of Crotalus viridis concolor | |
| MX2021011407A (es) | Proteinas de dominio ccn recombinantes y proteinas de fusion. | |
| Vindas et al. | A novel pentameric phospholipase A2 myotoxin (PophPLA2) from the venom of the pit viper Porthidium ophryomegas | |
| MX2022016365A (es) | Formulacion de alta concentracion de proteinas de union a antigeno de factor xii. | |
| AR128795A1 (es) | FORMULACIÓN LIOFILIZADA QUE COMPRENDE UNA PROTEÍNA DE FUSIÓN QUE INCLUYE a-GALACTOSIDASA A | |
| ES2421885T3 (es) | Polipéptidos y procedimiento para la detección específica de anticuerpos en pacientes con una infección por Borrelia | |
| MX2023011588A (es) | Constructos y metodos para aumentar la expresion de polipeptidos. |